ARA-290, also called cibinetide, is a small peptide built from a fragment of erythropoietin (EPO). Its key trick is that it keeps EPO’s tissue-protective and anti-inflammatory side while dropping the part that thickens blood. That design is why researchers studied it for nerve pain, particularly in sarcoidosis and diabetic neuropathy, rather than for boosting red blood cells.<\/p>\n
This guide covers what ARA-290 is, how it works, what the human evidence actually shows, how it was dosed in trials, the side effects reported so far, and the honest limits of the science. ARA-290 has some real human data, which sets it apart from many wellness peptides, but it never crossed the finish line to approval, and that context matters.<\/p>\n
At TrimRx, we believe understanding your options is the first step toward a health plan you can stick with. If you want to see whether a personalized, supervised program fits your goals, our free assessment quiz is a simple place to start.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
ARA-290 is a synthetic peptide of 11 amino acids, designed from a specific region of the erythropoietin molecule.<\/strong> EPO is best known for stimulating red blood cell production, but it also has a separate, lesser-known role in protecting and repairing tissue. ARA-290 was engineered to capture that second role on its own.<\/p>\n Quick Answer: ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) but engineered to skip EPO’s blood-thickening effect.<\/p>\n Under the research name cibinetide, the peptide completed several Phase 2 clinical trials, mostly in conditions involving nerve damage and inflammation. It earned FDA Orphan Drug status for sarcoidosis-associated neuropathy, a designation that supports development for rare diseases. Despite that, it was never approved, and active development appears to have stalled after about 2020.<\/p>\n So ARA-290 sits in an unusual spot: a peptide with legitimate clinical trials and a regulatory designation, but no approval and no commercial pharmaceutical product. That gap between “studied in humans” and “approved and available” is the single most important thing to understand about it. It is not a vaporware compound invented for marketing, but it is also not a finished medicine you can fill at a pharmacy with confidence in its proven benefit.<\/p>\n ARA-290 works by activating the innate repair receptor (IRR), a receptor complex that appears on tissue when it is injured or inflamed.<\/strong> EPO can activate this receptor, but it also triggers red blood cell production through a different receptor. ARA-290 was designed to hit only the repair receptor.<\/p>\n When the innate repair receptor is activated at a site of injury, it shifts the local environment away from inflammation and toward repair. In practical terms, that means calming overactive immune signaling and supporting the regeneration of damaged tissue, including small nerve fibers. Because the receptor only appears where there is damage, the action is somewhat self-targeting: it concentrates effect where tissue is actually injured.<\/p>\n The reason this design matters is safety. EPO itself raises red blood cell count and blood thickness, which can increase clot risk. By skipping the EPO receptor, ARA-290 avoids that hazard while keeping the repair signal, which is the whole point of building it.<\/p>\n ARA-290’s link to erythropoietin is the key to understanding both its appeal and its safety story.<\/strong> EPO is a hormone the body uses for two jobs. One is the famous one: telling bone marrow to make more red blood cells. The other is quieter: protecting and repairing tissue under stress, including nerves.<\/p>\n The problem with using EPO itself as a repair drug is the red blood cell effect. Raising red cell count thickens the blood, which can increase the risk of clots, stroke, and heart problems. That hazard is why EPO is tightly controlled and why it became infamous as a doping agent in endurance sports.<\/p>\n ARA-290 was built to solve this. By isolating the part of EPO that triggers tissue repair, and leaving out the part that drives red blood cell production, it aims to deliver protection without the clot risk. Trials supported that separation over the short term, reporting no signal for increased red blood cells. This is the single most important design feature of the molecule, and it is what makes a repair-focused EPO derivative thinkable in the first place.<\/p>\n The most studied benefit is relief of small fiber neuropathy, the nerve damage that causes burning, tingling, and pain, especially in conditions like sarcoidosis and diabetes.<\/strong> In trials, ARA-290 improved symptom scores and, importantly, measures of actual nerve regeneration.<\/p>\n Reported and studied benefits include:<\/p>\n The wellness market sometimes promotes ARA-290 broadly for recovery, inflammation, and longevity. Those wider uses are extrapolated from the neuropathy research, not directly proven. The real evidence is specific: inflammatory nerve damage, in small trials.<\/p>\n The clinical record for ARA-290 is small but real.<\/strong> The most cited study is a randomized, double-blind pilot trial in sarcoidosis patients with small fiber neuropathy, published in Molecular Medicine. It involved 22 patients and reported improvements in neuropathic symptoms along with objective signs of nerve repair.<\/p>\n The objective findings are what make this trial interesting. ARA-290 was associated with increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers. Those are measurable signs of nerve regrowth, not just self-reported feeling better. In a field where many peptides offer only anecdotes, having an objective regeneration endpoint move is meaningful.<\/p>\n That said, the results were not uniformly clean. In a dose-ranging study, pain scores did not clearly separate from placebo, even as other measures improved. A separate trial in type 2 diabetes reported improvements in metabolic control and neuropathic symptoms. The overall picture is a peptide with promising, repeatable signals in inflammatory nerve damage, supported by small trials that never scaled into large registration studies.<\/p>\n It is worth being blunt about the limits. These were Phase 2 pilot studies with modest patient numbers, and the program did not advance to approval. The evidence is enough to take ARA-290 seriously as a research compound. It is not enough to call it a proven treatment for anything.<\/p>\n In clinical trials, ARA-290 was given by subcutaneous injection.<\/strong> The dose most associated with positive results in the sarcoidosis neuropathy work was 4 mg per day. Trials typically ran over weeks, often around 28 days in the pilot studies, with some longer exposures in follow-up work.<\/p>\n The wellness-channel product is usually a subcutaneous injectable reconstituted from lyophilized powder. Self-directed protocols often cite the 4 mg daily figure from the trials, but those trials were supervised, in specific patient populations, and time-limited. Copying a trial dose at home from unregulated material is a different proposition than receiving it under monitoring.<\/p>\n Because ARA-290 is an investigational compound, dosing belongs with a licensed provider who can match it to your situation and watch for problems. We cover injectable peptide handling in our broader peptide-safety guides, and the same basics apply: sterile technique, verified sourcing, and oversight.<\/p>\n ARA-290 has a good short-term safety profile in trials.<\/strong> Across studies in sarcoidosis, type 2 diabetes, and other conditions, it was generally well tolerated. The most commonly reported side effects were mild: occasional injection-site reactions, headache, and minor gastrointestinal discomfort.<\/p>\n A particularly important safety point is what did not happen. Because ARA-290 skips the EPO receptor, trials reported no signal for increased red blood cell production or the dangerous blood-thickening that limits EPO. That clean hematologic profile was a central goal of the molecule’s design, and the trials supported it over the short term.<\/p>\n The caveats are the usual ones. Safety data comes from time-limited trials in patients with specific conditions. Long-term use in healthy people is not well studied, and unregulated sourcing introduces contamination and dosing risks separate from the molecule itself.<\/p>\n The people most likely to benefit are those with inflammatory small fiber neuropathy, the population where the evidence is strongest.<\/strong> Even then, because there is no approved product, the appropriate routes are a clinical trial or care from a knowledgeable physician.<\/p>\n You should avoid ARA-290 if you are pregnant, breastfeeding, under 18, or managing a serious medical condition without supervision. If your primary goal is weight management, ARA-290 is not a weight-loss peptide, and GLP-1 medications have far stronger and more direct evidence for that purpose.<\/p>\n Key Takeaway: The best human evidence is a small randomized trial in sarcoidosis patients with small fiber neuropathy, which showed symptom and nerve-fiber improvements.<\/p>\n The key comparison is with EPO itself.<\/strong> EPO boosts red blood cells and tissue protection but carries clot risk from blood thickening. ARA-290 was built to keep the tissue-protective half and drop the risky half, which is its defining advantage. It is not an EPO substitute for anemia and does not raise red blood cell count.<\/p>\n Compared with other repair-focused peptides like BPC-157, ARA-290 acts through a distinct mechanism (the innate repair receptor and anti-inflammatory signaling) and has a different, more nerve- and inflammation-focused evidence base. Each peptide targets repair through its own pathway, so they are not interchangeable.<\/p>\n Sourcing is where much of the practical risk lives.<\/strong> ARA-290 sold under a “research only, not for human use” label sits outside pharmaceutical quality control. Independent testing of research-chemical peptides has repeatedly found products that were underdosed, overdosed, mislabeled, or contaminated.<\/p>\n A few checks help. Ask whether the material is handled under sterile conditions and whether an independent certificate of analysis is available. Treat the absence of a certificate as a warning. Be wary of vendors promising clinical results from a product they cannot legally sell for human use. The cleaner path is a licensed provider or compounding pharmacy operating under medical oversight, where identity, purity, and sterility are actually verified.<\/p>\n This point is not a formality. Many disappointing or adverse peptide experiences trace back to the vial, not the molecule. With an injectable like ARA-290, what is actually in the vial determines everything, and the research-only supply chain offers no guarantee that the contents match the label.<\/p>\n Honesty matters most here.<\/strong> If you have inflammatory small fiber neuropathy and you receive ARA-290 under medical care, the trial data suggests some people see symptom improvement and signs of nerve regeneration over several weeks. That is a genuine, if modest and not guaranteed, expectation grounded in real studies.<\/p>\n If you are a healthy adult buying ARA-290 hoping for general recovery, anti-inflammation, or longevity benefits, the expectation should be much more uncertain. The innate repair receptor only appears where tissue is injured or inflamed, so in the absence of active damage there may be little for the peptide to act on. The broad wellness uses are extrapolations, and anecdotal reports of feeling better are unverified and prone to placebo effects.<\/p>\n Trial timelines ran over weeks, often around 28 days in the pilot work, with some longer exposures. There is no validated wellness timeline, so any specific “results in X days” claim for general use is invented rather than measured. Set expectations conservatively, and remember that the strongest data is narrow and disease-specific.<\/p>\n Several claims circulate that the evidence does not support.<\/strong> The first is that ARA-290 is a proven treatment ready for everyday use. It is not. It holds Orphan Drug status but no approval, and its development stalled after about 2020.<\/p>\n The second myth is that it works like EPO for boosting energy or athletic performance through more red blood cells. It does the opposite by design: it was engineered to skip the red-blood-cell effect entirely. The third is that it is a general anti-inflammatory you can take for any ache. Its mechanism is tied to the innate repair receptor on injured tissue, not a broad systemic anti-inflammatory like an NSAID.<\/p>\n The fourth, and most important for safety, is that “research-grade” means high quality. The research-only label is a legal status, not a quality guarantee, and it often means less oversight rather than more.<\/p>\n ARA-290 is not a weight-loss peptide.<\/strong> While a diabetes trial reported some improvement in metabolic control, that is a long way from meaningful, reliable weight loss, and it was a secondary finding in a small study. There is no trial evidence that ARA-290 produces significant fat loss or appetite change.<\/p>\n For weight and metabolic goals, the proven tools are GLP-1 and dual-agonist medications, lifestyle change, and structured medical support. The STEP 1 trial (Wilding 2021, NEJM) showed about 15 percent average weight loss with semaglutide, and SURMOUNT-1 (Jastreboff 2022, NEJM) showed tirzepatide reaching up to roughly 21 percent. ARA-290 has nothing comparable, so for weight loss it is the wrong tool.<\/p>\n There is one indirect connection worth understanding. People with diabetes-related neuropathy are often managing weight and blood sugar at the same time, which is part of why a diabetes neuropathy trial existed. But treating the nerve pain and treating the weight are separate jobs with separate tools. ARA-290 was studied for the nerve side, not for producing weight loss, and conflating the two oversells what it can do.<\/p>\n If you are exploring ARA-290 because of nerve pain, inflammation, or general recovery, the smart first step is to be clear about what the evidence actually supports.<\/strong> It has real but limited human data in inflammatory neuropathy, no approval, and stalled development. That is a meaningfully different story than the broad longevity claims sometimes attached to it.<\/p>\n At TrimRX, we focus on evidence-backed, medically supervised care for weight management with compounded semaglutide and tirzepatide, and we are expanding thoughtfully into peptides. If you are unsure where to start, our free assessment quiz can help you see whether a personalized program is a reasonable fit, with a licensed provider involved rather than a guess from a forum.<\/p>\n Bottom line: It has a good short-term safety record in trials, with no signal for the dangerous blood effects that limit EPO itself.<\/p>\n Yes. ARA-290 is the research code and cibinetide is the drug name for the same 11-amino-acid peptide derived from erythropoietin. It completed several Phase 2 trials but was never approved.<\/p>\n No. It was specifically engineered to skip the EPO receptor that drives red blood cell production. Trials reported no signal for the blood-thickening effect that limits EPO, which was the main reason it was designed.<\/p>\n Small fiber neuropathy in sarcoidosis has the best evidence. A randomized pilot trial reported improvements in symptoms and in objective nerve fiber regeneration at a 4 mg daily dose.<\/p>\n No. It holds FDA Orphan Drug status for sarcoidosis-associated neuropathy, which supports development of rare-disease treatments, but it was never approved and development stalled after about 2020.<\/p>\n No. It is not a weight-loss peptide. A diabetes trial noted some metabolic improvement, but there is no evidence of meaningful fat loss. GLP-1 medications are far better proven for weight goals.<\/p>\n Buying “research only” powder carries real risks around purity, sterility, and dosing accuracy. The safest route is medical supervision through a licensed provider rather than self-sourcing unregulated material.<\/p>\n The pilot sarcoidosis neuropathy trial ran about 28 days, with some follow-up and longer exposures in related work. There is no validated timeline for general wellness use, so claims of a set result window for that purpose are not based on data.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" ARA-290, also called cibinetide, is a small peptide built from a fragment of erythropoietin (EPO).<\/p>\n","protected":false},"author":11,"featured_media":104831,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[],"class_list":["post-104832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/104832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=104832"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/104832\/revisions"}],"predecessor-version":[{"id":107512,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/104832\/revisions\/107512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/104831"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=104832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=104832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=104832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Does ARA-290 Work in the Body?<\/h2>\n
Why Does the EPO Connection Matter?<\/h2>\n
What Are the Potential Benefits of ARA-290?<\/h2>\n
\n
What Does the Clinical Trial Evidence Show?<\/h2>\n
How Is ARA-290 Dosed in Research?<\/h2>\n
What Are the Side Effects of ARA-290?<\/h2>\n
Who Might Consider ARA-290, and WHO Should Avoid It?<\/h2>\n
How Does ARA-290 Compare to EPO and Other Peptides?<\/h2>\n
How to Evaluate ARA-290 Sourcing and Quality<\/h2>\n
What Results Can a Realistic User Expect?<\/h2>\n
Common Myths About ARA-290<\/h2>\n
ARA-290 and Weight or Metabolic Goals<\/h2>\n
The Path Forward with TrimRx<\/h2>\n
FAQ<\/h2>\n
Is ARA-290 the Same as Cibinetide?<\/h3>\n
Does ARA-290 Raise Red Blood Cells Like EPO?<\/h3>\n
What Condition Has the Best ARA-290 Evidence?<\/h3>\n
Is ARA-290 FDA Approved?<\/h3>\n
Does ARA-290 Help with Weight Loss?<\/h3>\n
Is It Safe to Buy ARA-290 From Research-chemical Sites?<\/h3>\n
How Long Did ARA-290 Trials Run?<\/h3>\n